Track topics on Twitter Track topics that are important to you
Novartis has announced positive data from its PREVENT trial, which evaluated the safety and efficacy of Cosentyx (secukinumab) for patients with non-radiographic axial spondyloarthritis, ultimately showing a clinically meaningful reduction in disease activity versus placebo.
The ongoing Phase 3 trial met it primary endpoint at Week 52 and demonstrated a sustained response and a safety profile that was consistent with previous clinical trials.NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...